patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_924999 | REC_0012801 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 22 | 14.9 | 65 | female | 1 | 13 | 5.4 | 0 | sotorasib 960 mg daily | 43 | false | MSS | 2026-03-15T05:36:00.119135+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848012 | REC_0012802 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 13.2 | 66 | female | 0 | 14 | 7.9 | 6 | entrectinib 600 mg daily | 15.2 | true | MSS | 2026-03-15T05:36:00.119453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747406 | REC_0012803 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 5.4 | 67 | female | 0 | 17 | 3.4 | 2 | pembrolizumab 200 mg q3w | 18.2 | true | MSS | 2026-03-15T05:36:00.119772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_725887 | REC_0012804 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 8.8 | 65 | male | 0 | 25 | 3.5 | 5 | osimertinib 80 mg daily | 15.6 | false | MSS | 2026-03-15T05:36:00.120118+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_335965 | REC_0012805 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 15.2 | 67 | female | 1 | 19 | 5.7 | 1 | sotorasib 960 mg daily | 16.3 | true | MSS | 2026-03-15T05:36:00.120469+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_299033 | REC_0012806 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 14 | 74 | male | 2 | 11 | 6.2 | 5 | osimertinib 80 mg daily | 11.6 | true | MSS | 2026-03-15T05:36:00.120966+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405529 | REC_0012807 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 10.9 | 69 | female | 0 | 20 | 5 | 5 | alectinib 600 mg BID | 23.6 | true | MSI-H | 2026-03-15T05:36:00.121313+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626725 | REC_0012808 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 11.2 | 60 | male | 0 | 12 | 7.6 | 1 | sotorasib 960 mg daily | 14.9 | true | MSI-H | 2026-03-15T05:36:00.121615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_481053 | REC_0012809 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 17.2 | 80 | male | 2 | 19 | 5.4 | 4 | sotorasib 960 mg daily | 4.1 | true | MSS | 2026-03-15T05:36:00.121909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670913 | REC_0012810 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 9.1 | 79 | male | 1 | 18 | 9.1 | 2 | osimertinib 80 mg daily | 17.4 | false | MSS | 2026-03-15T05:36:00.122202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578747 | REC_0012811 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 12 | 64 | female | 1 | 2 | 4.3 | 3 | sotorasib 960 mg daily | 7.5 | true | MSI-H | 2026-03-15T05:36:00.122490+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729091 | REC_0012812 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 37 | 13.5 | 60 | female | 0 | 16 | 6 | 0 | osimertinib 80 mg daily | 27.1 | false | MSI-H | 2026-03-15T05:36:00.122788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590659 | REC_0012813 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.4 | 64 | male | 0 | 18 | 6.2 | 6 | alectinib 600 mg BID | 4.3 | true | MSI-H | 2026-03-15T05:36:00.123095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570227 | REC_0012814 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 12.8 | 70 | female | 1 | 14 | 5.2 | 7 | sotorasib 960 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:36:00.123398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_477727 | REC_0012815 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 3.6 | 68 | female | 1 | 19 | 4.5 | 3 | alectinib 600 mg BID | 7.7 | true | MSS | 2026-03-15T05:36:00.123707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324477 | REC_0012816 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 9.1 | 70 | female | 1 | 20 | 5.4 | 2 | entrectinib 600 mg daily | 20.4 | false | MSS | 2026-03-15T05:36:00.124005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860712 | REC_0012817 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 15 | 12 | 61 | female | 1 | 14 | 4.6 | 7 | entrectinib 600 mg daily | 5.1 | true | MSI-H | 2026-03-15T05:36:00.124432+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_195532 | REC_0012818 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 16 | 83 | male | 1 | 8 | 7.9 | 5 | osimertinib 80 mg daily | 8.8 | false | MSI-H | 2026-03-15T05:36:00.124769+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984671 | REC_0012819 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 10.7 | 70 | female | 0 | 15 | 5.3 | 8 | osimertinib 80 mg daily | 12.6 | false | MSI-H | 2026-03-15T05:36:00.125237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_595403 | REC_0012820 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 13.9 | 66 | female | 1 | 10 | 4 | 6 | osimertinib 80 mg daily | 12.5 | false | MSI-H | 2026-03-15T05:36:00.125562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772758 | REC_0012821 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.5 | 67 | female | 1 | 66 | 4.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 6.2 | false | MSS | 2026-03-15T05:36:00.125870+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752320 | REC_0012822 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 14.3 | 62 | female | 0 | 7 | 5.2 | 6 | osimertinib 80 mg daily | 5.1 | true | MSI-H | 2026-03-15T05:36:00.126166+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_357023 | REC_0012823 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 15.9 | 57 | female | 0 | 27 | 5.3 | 6 | osimertinib 80 mg daily | 10.1 | true | MSI-H | 2026-03-15T05:36:00.126462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702839 | REC_0012824 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 5 | 58 | female | 1 | 53 | 6.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 17.6 | false | MSS | 2026-03-15T05:36:00.126742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187574 | REC_0012825 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 12.3 | 57 | male | 1 | 9 | 4.5 | 8 | pembrolizumab 200 mg q3w | 20.2 | true | MSS | 2026-03-15T05:36:00.127032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_979175 | REC_0012826 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 5.4 | 64 | female | 1 | 7 | 4.9 | 5 | pembrolizumab 200 mg q3w | 12.6 | false | MSS | 2026-03-15T05:36:00.127315+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957939 | REC_0012827 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 7.5 | 66 | male | 1 | 5 | 5.3 | 7 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:36:00.127599+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346245 | REC_0012828 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 15 | 6.7 | 58 | male | 0 | 30 | 5.4 | 1 | entrectinib 600 mg daily | 22 | true | MSS | 2026-03-15T05:36:00.127864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742561 | REC_0012829 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 3.8 | 81 | female | 1 | 50 | 7 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.4 | false | MSS | 2026-03-15T05:36:00.128216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907341 | REC_0012830 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 8.2 | 68 | female | 0 | 15 | 5.5 | 5 | alectinib 600 mg BID | 10.2 | true | MSS | 2026-03-15T05:36:00.128532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487329 | REC_0012831 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 15.2 | 84 | female | 1 | 16 | 4.8 | 7 | entrectinib 600 mg daily | 4 | false | MSI-H | 2026-03-15T05:36:00.128826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342009 | REC_0012832 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 7.9 | 51 | female | 0 | 34 | 6.3 | 6 | pembrolizumab 200 mg q3w | 10.7 | false | MSS | 2026-03-15T05:36:00.129283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735374 | REC_0012833 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 2 | 71 | female | 3 | 13 | 7.2 | 1 | pembrolizumab 200 mg q3w | 6.7 | false | MSS | 2026-03-15T05:36:00.129599+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955070 | REC_0012834 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 25 | 11.5 | 74 | female | 2 | 5 | 2.7 | 0 | osimertinib 80 mg daily | 37 | true | MSI-H | 2026-03-15T05:36:00.129895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948586 | REC_0012835 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 7.9 | 60 | female | 1 | 18 | 5.8 | 6 | entrectinib 600 mg daily | 14.2 | false | MSS | 2026-03-15T05:36:00.130210+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964180 | REC_0012836 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 16.5 | 63 | female | 0 | 20 | 5.6 | 5 | entrectinib 600 mg daily | 4.2 | false | MSS | 2026-03-15T05:36:00.130497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169378 | REC_0012837 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 17 | 73 | female | 1 | 16 | 5.7 | 6 | entrectinib 600 mg daily | 20.2 | true | MSS | 2026-03-15T05:36:00.130783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416287 | REC_0012838 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12 | 70 | female | 2 | 21 | 4.2 | 3 | entrectinib 600 mg daily | 9.9 | false | MSS | 2026-03-15T05:36:00.131091+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517308 | REC_0012839 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 20 | 7 | 70 | female | 2 | 12 | 6.1 | 1 | pembrolizumab 200 mg q3w | 8.9 | false | MSS | 2026-03-15T05:36:00.131371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407305 | REC_0012840 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 13 | 63 | male | 0 | 16 | 2.9 | 1 | alectinib 600 mg BID | 10.2 | false | MSI-H | 2026-03-15T05:36:00.131671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293475 | REC_0012841 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 12 | 55 | female | 1 | 6 | 6.6 | 6 | osimertinib 80 mg daily | 14.7 | true | MSS | 2026-03-15T05:36:00.132010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349745 | REC_0012842 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 15 | 6.8 | 61 | female | 1 | 63 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.2 | false | MSS | 2026-03-15T05:36:00.132434+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246672 | REC_0012843 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 17 | 10.7 | 82 | male | 1 | 37 | 3.4 | 0 | pembrolizumab 200 mg q3w | 21.8 | false | MSI-H | 2026-03-15T05:36:00.132803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700766 | REC_0012844 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 21 | 17.8 | 69 | female | 0 | 13 | 5.2 | 0 | osimertinib 80 mg daily | 40.6 | false | MSI-H | 2026-03-15T05:36:00.133144+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842173 | REC_0012845 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 11.6 | 64 | female | 0 | 17 | 6 | 6 | osimertinib 80 mg daily | 9.6 | true | MSI-H | 2026-03-15T05:36:00.133633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419390 | REC_0012846 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6.2 | 59 | female | 0 | 8 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.1 | false | MSS | 2026-03-15T05:36:00.133963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110671 | REC_0012847 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 5.3 | 64 | female | 1 | 54 | 3.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.3 | true | MSS | 2026-03-15T05:36:00.134263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181870 | REC_0012848 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 7.5 | 59 | male | 0 | 48 | 4.7 | 5 | pembrolizumab 200 mg q3w | 8.4 | true | MSS | 2026-03-15T05:36:00.134568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451494 | REC_0012849 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 30 | 6.5 | 62 | female | 1 | 60 | 6 | 1 | pembrolizumab 200 mg q3w | 17.4 | false | MSS | 2026-03-15T05:36:00.134886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_185432 | REC_0012850 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4 | 73 | male | 2 | 42 | 3.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 10 | false | MSS | 2026-03-15T05:36:00.135228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_912456 | REC_0012851 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 14.4 | 62 | female | 1 | 3 | 6 | 5 | osimertinib 80 mg daily | 6.9 | false | MSS | 2026-03-15T05:36:00.135546+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153266 | REC_0012852 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 17.6 | 46 | male | 0 | 13 | 6.1 | 2 | entrectinib 600 mg daily | 14.6 | false | MSS | 2026-03-15T05:36:00.135852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306007 | REC_0012853 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 9.8 | 72 | female | 2 | 8 | 6.4 | 1 | sotorasib 960 mg daily | 24.7 | true | MSS | 2026-03-15T05:36:00.136212+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_283211 | REC_0012854 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 11.4 | 74 | female | 2 | 21 | 5.7 | 9 | osimertinib 80 mg daily | 13.4 | true | MSS | 2026-03-15T05:36:00.136527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320073 | REC_0012855 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 24 | 6.7 | 66 | female | 0 | 28 | 5.4 | 0 | carboplatin + paclitaxel + pembrolizumab | 60.2 | true | MSS | 2026-03-15T05:36:00.136822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774477 | REC_0012856 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 13.9 | 66 | female | 1 | 21 | 6.2 | 6 | sotorasib 960 mg daily | 6.2 | false | MSI-H | 2026-03-15T05:36:00.137146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197314 | REC_0012857 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 12.9 | 62 | male | 0 | 26 | 6.3 | 4 | alectinib 600 mg BID | 13.8 | true | MSS | 2026-03-15T05:36:00.137439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796454 | REC_0012858 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 15.5 | 82 | female | 1 | 21 | 5.9 | 1 | osimertinib 80 mg daily | 22.5 | true | MSI-H | 2026-03-15T05:36:00.137866+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375115 | REC_0012859 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 12.7 | 75 | female | 1 | 18 | 3 | 2 | osimertinib 80 mg daily | 28.6 | true | MSI-H | 2026-03-15T05:36:00.138232+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198410 | REC_0012860 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 12.8 | 74 | female | 1 | 14 | 6 | 4 | sotorasib 960 mg daily | 13.7 | true | MSI-H | 2026-03-15T05:36:00.138543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_102134 | REC_0012861 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 12.6 | 69 | female | 1 | 13 | 6.5 | 3 | entrectinib 600 mg daily | 8.6 | false | MSS | 2026-03-15T05:36:00.138842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275647 | REC_0012862 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 11.4 | 63 | male | 1 | 0 | 5.3 | 2 | sotorasib 960 mg daily | 17.9 | false | MSS | 2026-03-15T05:36:00.139146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931281 | REC_0012863 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 6 | 55 | male | 1 | 46 | 3.5 | 7 | pembrolizumab 200 mg q3w | 8.3 | true | MSS | 2026-03-15T05:36:00.139488+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839328 | REC_0012864 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.1 | 66 | female | 1 | 22 | 6.5 | 1 | osimertinib 80 mg daily | 10.5 | false | MSS | 2026-03-15T05:36:00.139845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139655 | REC_0012865 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 17.6 | 64 | male | 0 | 14 | 5.1 | 2 | osimertinib 80 mg daily | 11 | false | MSI-H | 2026-03-15T05:36:00.140263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128002 | REC_0012866 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 10 | 52 | female | 0 | 4 | 5.4 | 5 | pembrolizumab 200 mg q3w | 12.4 | false | MSI-H | 2026-03-15T05:36:00.140612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255886 | REC_0012867 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 5.9 | 69 | female | 0 | 10 | 6.1 | 6 | pembrolizumab 200 mg q3w | 7 | true | MSS | 2026-03-15T05:36:00.140917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454871 | REC_0012868 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 16.9 | 66 | female | 1 | 23 | 5.7 | 1 | alectinib 600 mg BID | 15.5 | false | MSI-H | 2026-03-15T05:36:00.141202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415970 | REC_0012869 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 6.4 | 61 | female | 0 | 15 | 5.7 | 8 | pembrolizumab 200 mg q3w | 6.9 | false | MSS | 2026-03-15T05:36:00.141489+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700501 | REC_0012870 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 35 | 5.3 | 76 | female | 2 | 26 | 5.8 | 7 | pembrolizumab 200 mg q3w | 11 | false | MSS | 2026-03-15T05:36:00.141775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264254 | REC_0012871 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 16 | 18.3 | 83 | female | 2 | 9 | 6.9 | 2 | osimertinib 80 mg daily | 18.1 | false | MSI-H | 2026-03-15T05:36:00.142219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_272827 | REC_0012872 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 4.8 | 63 | female | 1 | 35 | 5 | 8 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:36:00.142530+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769243 | REC_0012873 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 12.3 | 60 | male | 0 | 17 | 6 | 2 | entrectinib 600 mg daily | 21.8 | true | MSS | 2026-03-15T05:36:00.142833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_693496 | REC_0012874 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 3.8 | 60 | female | 0 | 24 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 28.8 | true | MSS | 2026-03-15T05:36:00.143122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557565 | REC_0012875 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 3.4 | 54 | male | 0 | 39 | 4.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 16.2 | true | MSS | 2026-03-15T05:36:00.143406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253336 | REC_0012876 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 34 | 17.8 | 68 | male | 0 | 15 | 4.9 | 4 | sotorasib 960 mg daily | 4.8 | true | MSS | 2026-03-15T05:36:00.143698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210671 | REC_0012877 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 10.6 | 75 | female | 2 | 23 | 4.9 | 7 | alectinib 600 mg BID | 14.4 | false | MSI-H | 2026-03-15T05:36:00.143984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874032 | REC_0012878 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 14.6 | 70 | male | 2 | 10 | 6.6 | 4 | osimertinib 80 mg daily | 14.4 | false | MSS | 2026-03-15T05:36:00.144346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345217 | REC_0012879 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 21 | 3.2 | 76 | male | 2 | 31 | 4.4 | 0 | pembrolizumab 200 mg q3w | 47 | false | MSS | 2026-03-15T05:36:00.144648+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_891721 | REC_0012880 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 7.1 | 59 | female | 0 | 11 | 6.7 | 2 | pembrolizumab 200 mg q3w | 6 | true | MSS | 2026-03-15T05:36:00.144943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313252 | REC_0012881 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 18.5 | 72 | female | 2 | 13 | 5.8 | 2 | osimertinib 80 mg daily | 17.9 | true | MSS | 2026-03-15T05:36:00.145230+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_917055 | REC_0012882 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 9.4 | 65 | male | 1 | 27 | 4.8 | 2 | alectinib 600 mg BID | 12.9 | true | MSS | 2026-03-15T05:36:00.145505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175990 | REC_0012883 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 36 | 14.2 | 56 | female | 1 | 12 | 4.8 | 6 | osimertinib 80 mg daily | 7.4 | false | MSS | 2026-03-15T05:36:00.145788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221988 | REC_0012884 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 5.7 | 65 | female | 0 | 13 | 6.5 | 2 | alectinib 600 mg BID | 21 | false | MSS | 2026-03-15T05:36:00.146208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246745 | REC_0012885 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 14.9 | 79 | female | 1 | 19 | 5.9 | 2 | sotorasib 960 mg daily | 22 | false | MSI-H | 2026-03-15T05:36:00.146508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887890 | REC_0012886 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 12.3 | 69 | female | 1 | 19 | 3.1 | 7 | pembrolizumab 200 mg q3w | 9.1 | false | MSS | 2026-03-15T05:36:00.146798+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389821 | REC_0012887 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 11 | 71 | female | 2 | 15 | 4.1 | 6 | osimertinib 80 mg daily | 5.1 | true | MSI-H | 2026-03-15T05:36:00.147076+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407744 | REC_0012888 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 11.9 | 65 | male | 1 | 12 | 5 | 9 | alectinib 600 mg BID | 12.3 | true | MSS | 2026-03-15T05:36:00.147357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174242 | REC_0012889 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 10.9 | 71 | male | 1 | 15 | 5.5 | 6 | sotorasib 960 mg daily | 13.4 | true | MSS | 2026-03-15T05:36:00.147654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970060 | REC_0012890 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 32 | 16.1 | 69 | female | 1 | 20 | 4.9 | 2 | entrectinib 600 mg daily | 10.9 | true | MSS | 2026-03-15T05:36:00.147942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780311 | REC_0012891 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 19.6 | 75 | female | 2 | 18 | 5.5 | 5 | osimertinib 80 mg daily | 9.1 | false | MSS | 2026-03-15T05:36:00.148278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930095 | REC_0012892 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 16.5 | 57 | male | 1 | 23 | 6.1 | 7 | entrectinib 600 mg daily | 14.4 | false | MSI-H | 2026-03-15T05:36:00.148623+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498946 | REC_0012893 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 15.2 | 65 | female | 0 | 17 | 6.1 | 1 | sotorasib 960 mg daily | 20.1 | false | MSI-H | 2026-03-15T05:36:00.148974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_228249 | REC_0012894 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 5.9 | 64 | female | 1 | 9 | 5.8 | 2 | pembrolizumab 200 mg q3w | 14.2 | false | MSS | 2026-03-15T05:36:00.149332+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765240 | REC_0012895 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 12.5 | 70 | female | 1 | 19 | 5.2 | 7 | sotorasib 960 mg daily | 10.2 | true | MSS | 2026-03-15T05:36:00.149687+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534819 | REC_0012896 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 4.6 | 65 | female | 1 | 34 | 5.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 25.8 | true | MSS | 2026-03-15T05:36:00.149999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812325 | REC_0012897 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 5.3 | 63 | female | 0 | 58 | 6.7 | 6 | pembrolizumab 200 mg q3w | 12.8 | true | MSS | 2026-03-15T05:36:00.150481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_631955 | REC_0012898 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 10.5 | 67 | female | 0 | 11 | 5.6 | 1 | alectinib 600 mg BID | 25.1 | false | MSS | 2026-03-15T05:36:00.150847+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_193494 | REC_0012899 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 34 | 10.2 | 80 | male | 2 | 16 | 6.2 | 6 | sotorasib 960 mg daily | 8.5 | true | MSI-H | 2026-03-15T05:36:00.151170+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456002 | REC_0012900 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 35 | 10.3 | 68 | female | 1 | 8 | 6.2 | 5 | osimertinib 80 mg daily | 17 | true | MSS | 2026-03-15T05:36:00.151498+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.